富祥药业：2025年前三季度净利润约-6275万元

Group 1 - The core viewpoint of the news is that Fuxiang Pharmaceutical reported a significant decline in revenue and incurred a net loss in the third quarter of 2025 [1] - For the first three quarters of 2025, the company's revenue was approximately 769 million yuan, representing a year-on-year decrease of 21.24% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 62.75 million yuan, with basic earnings per share showing a loss of 0.12 yuan [1] Group 2 - As of the report, Fuxiang Pharmaceutical has a market capitalization of 5.4 billion yuan [2]